Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 18/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885718 | 0.80 | AHR (1.00) | AHRFLT1 | |
| SCHEMBL29353294 | 0.80 | AHR (1.00) | AHRFLT1 | |
| SCHEMBL7049101 | 0.75 | AHR (0.70) | AHRFLT1GAA | |
| SCHEMBL2461446 | 0.75 | AHR (0.67) | AHRFLT1 | |
| 2,3,7,8-Tetrachlorodibenzo-P-Dioxin SCHEMBL29364019 | 0.74 | AHR (1.00) | AHRFLT1GAAALPL | |
| 2,3,7,8-Tetrachlorodibenzo-P-Dioxin SCHEMBL8939 | 0.74 | AHR (1.00) | AHRFLT1GAAALPL | |
| 2,3,7,8-Tetrachlorodibenzo-P-Dioxin SCHEMBL29350382 | 0.74 | AHR (1.00) | AHRFLT1GAAALPL | |
| SCHEMBL5967950 | 0.72 | AHR (0.86) | AHRFLT1 | |
| SCHEMBL9579657 | 0.72 | AHR (0.86) | AHRFLT1 | |
| SCHEMBL30118871 | 0.72 | AHR (0.86) | AHRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030108955-A1 | Dioxin derivatives and method of measurement therewith | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1256579-A1 | DIOXIN DERIVATIVES AND METHOD OF MEASUREMENT THEREWITH | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0251635-B1 | Monoclonal antibodies and method for detecting dioxins and dibenzofurans | UNIV CALIFORNIA (US) | 1994-08-10 | — | — | EP | disclosed |
| US-4798807-A | HYBRIDOMAS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-01-17 | — | — | US | disclosed |
| EP-0251635-A2 | Monoclonal antibodies and method for detecting dioxins and dibenzofurans | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108955-A1 | Dioxin derivatives and method of measurement therewith | PRMT1, PADI1, PADI2 | AHR 225/4885FLT1 503/4885GAA 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.